Document is current
Any future updates will be listed below
-
Authors
Alcon, Clara
Martín, Fernando https://orcid.org/0000-0002-3496-9093
Prada, Estela https://orcid.org/0000-0003-4611-1120
Mora, Jaume
Soriano, Aroa https://orcid.org/0000-0001-9659-1471
Guillén, Gabriela https://orcid.org/0000-0001-5632-2672
Gallego, Soledad https://orcid.org/0000-0002-4712-9624
Roma, Josep https://orcid.org/0000-0001-7692-6123
Samitier, Josep https://orcid.org/0000-0002-1140-3679
Villanueva, Alberto https://orcid.org/0000-0001-5164-0006
Montero, Joan https://orcid.org/0000-0002-9192-4836
- License Information
-
More Information
Article History
Received: 4 November 2021
Revised: 18 February 2022
Accepted: 16 March 2022
First Online: 7 April 2022
Conflict of interest
: JM was a paid consultant for Oncoheroes Biosciences and Vivid Biosciences, is an unpaid board member for The Society for Functional Precision Medicine and he is currently collaborating with AstraZeneca. AV is cofounder of the Spin-off of Xenopat S.L and has ownership interests. The following are U.S. Patents regarding BH3 profiling owned by Dana-Farber: 10,393,733; 9,902,759; 9,856,303; 9,540,674; 8,221,966; and 7,868,133. JM is a co-inventor on a patent application WO2014047342A1 held/submitted by Dana-Farber Cancer Institute that covers dynamic BH3 profiling, licensed and with royalties paid. No potential conflicts of interest were disclosed by the other authors.
